Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Pluristem’s Commercial Scale Cell Mfg. Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

FDA Approves Pluristem’s Commercial Scale Cell Mfg. Facility

Will produce PLacental eXpanded (PLX) cell products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pluristem Therapeutics, Inc. has received approval from the FDA for the comparability studies of its PLacental eXpanded (PLX) cell products and was granted approval for the manufacture these products at its new commercial-scale cell manufacturing facility.

“We believe we have the largest, scalable, most efficient, most consistent and controlled process for manufacturing cell therapies,” said Zami Aberman, chairman and chief executive officer of Pluristem. “Knowing that the ‘Process is the Product’ in cell therapy, we have established our leadership position in the industry by focusing on our 3D commercial scale cell manufacturing processes. To be a successful company in the industry, we believe it is imperative to possess and control the manufacturing processes we have developed at Pluristem. We believe this FDA approval, combined with the approval given by the Paul-Ehrlich-Institute (PEI) of Germany, is an indication that these regulatory bodies see our 3D manufacturing process as a valid and sustainable commercial scale solution for potential cell therapies.”

At its new GMP manufacturing facility, the company has implemented its fully automated 3D cell expansion manufacturing platform that uses high-throughput culturing technologies, 3D bioreactors, and downstream equipment. According to the company, the facility has the ability to produce approximately 150,000 doses of PLX cells annually, with batch-to-batch consistency.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics